Neihulizumab

DB16698InvestigationalProtein Based Therapies

Neihulizumab is a novel immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), thereby preferentially inducing apoptosis in late stage activated T cells.

Mechanism: Pharmacologically active on P-selectin glycoprotein ligand 1
Curator reviewed
Code names: AbGn-168H

Resolves to

Compound

UNII615637S5PE

Targets

Q14242SELPLG

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Neihulizumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account